Senseonics has announced it raised $20 million of PE financing.

Senseonics, headquartered in Germantown, Md., focuses on the development and commercialization of a fully implantable, long-term continuous glucose monitoring system.

Participating in the financing round were current investors Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, New Enterprise Associates and other partners.

Senseonics said it plans to use proceeds from the round to continue product development initiatives including completing trials in Europe, obtaining CE mark and initiating IDE trials in the U.S.